News

Choosing the Right Excipient for Optimal Dosage Form Performance in Immunocompromised Patients

A research recent featured in the Journal of AIDS and HIV Research showed the potential of Low-Dose Naltrexone (LDN) in stabilizing CD4 counts among untreated HIV+ individuals and amplifying CD4 count increments when used alongside antiretroviral therapy. This breakthrough offers promising prospects for advancing HIV management strategies. Compounding of LDN capsules In the realm of … Continued

Read more
News

Enhancing Psoriasis Treatment with Advanced Compounding Solutions

Psoriasis, a widespread autoimmune condition, impacts approximately 125 million individuals globally. A majority of psoriasis sufferers, around 80%, experience a milder form of the disease that can be effectively managed using topical treatments. These topical solutions serve various purposes, with different formulations suited for different aspects of the condition. Recent advancements in psoriasis research have … Continued

Read more
News

Addressing the specific needs of Pediatric and Geriatric patients through Oral Suspensions

Pediatric and geriatric patients require careful consideration when it comes to the administration of medication to ensure both safety and efficacy. Physiological characteristics of children and elderly differ considerably from that of adults; they may not be able to metabolize or eliminate active substances and excipients in pharmaceutical products in the same manner. Personalized medicine, … Continued

Read more
ESG

Build the Organization of the Future: Fagron’s Commitment to ESG and Stakeholder Engagement

Stakeholder engagement ESG (Environment, Social, and Governance) lies at the core of Fagron’s activities and strategy. Fagron products and services contribute every day to improving people’s health. As a global company with the purpose to create the future of personalizing medicine, we aim to produce all our products ethically and responsibly. We strive to create long-term value for … Continued

Read more